Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Operating Expenses: 2017-2025

Historic Operating Expenses for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to $40.7 million.

  • Dianthus Therapeutics' Operating Expenses rose 26.85% to $40.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $143.4 million, marking a year-over-year increase of 62.44%. This contributed to the annual value of $108.1 million for FY2024, which is 111.96% up from last year.
  • As of Q3 2025, Dianthus Therapeutics' Operating Expenses stood at $40.7 million, which was up 15.84% from $35.1 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Operating Expenses ranged from a high of $40.7 million in Q3 2025 and a low of $8.2 million during Q1 2023.
  • Moreover, its 3-year median value for Operating Expenses was $24.1 million (2024), whereas its average is $24.5 million.
  • Data for Dianthus Therapeutics' Operating Expenses shows a peak YoY surged of 147.83% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Dianthus Therapeutics' Operating Expenses stood at $11.9 million in 2022, then grew by 13.02% to $13.4 million in 2023, then spiked by 147.83% to $33.2 million in 2024, then rose by 26.85% to $40.7 million in 2025.
  • Its last three reported values are $40.7 million in Q3 2025, $35.1 million for Q2 2025, and $34.3 million during Q1 2025.